Project

Novel therapeutic agents for the treatment of early T-cell progenitor leukemia

Duration
01 January 2015 → 31 December 2017
Funding
Research Foundation - Flanders (FWO)
Research disciplines
  • Medical and health sciences
    • Laboratory medicine
    • Palliative care and end-of-life care
    • Regenerative medicine
    • Other basic sciences
    • Laboratory medicine
    • Palliative care and end-of-life care
    • Regenerative medicine
    • Other clinical sciences
    • Other health sciences
    • Nursing
    • Other paramedical sciences
    • Laboratory medicine
    • Palliative care and end-of-life care
    • Regenerative medicine
    • Other translational sciences
    • Other medical and health sciences
Keywords
T cells biomolecules
 
Project description

T-cell acute lymphoblastic leukemia (T-ALL) accounts for 15% of pediatric and 25% of adult ALL cases and was originally identified as a highly aggressive tumor associated with poor prognosis. Recent studies have identified a subset of T-ALLs whose transcriptional programs resemble those of immature early T-cell progenitors (ETP) and hematopoietic stem cells. Importantly, these so-called ETP-ALLs have strong clinical relevance since they are characterized by early treatment failure and an extremely poor prognosis.
The ultimate goal of this research proposal is to identify novel therapeutic agents for the treatment of ETP-ALL. Given that these patients completely fail current chemotherapy treatment schedules, this project addresses the urgent need to identify novel therapies in this aggressive haematological malignancy. Therefore, this project holds the promise for significantly ameliorating clinical care in
the near future.